Kyfora BioTM Launches AmpliFect™ GMP Transfection Enhancer for Cell and Gene Therapy Manufacturing
AmpliFect™ GMP Transfection Enhancer boosts viral titers lowering production costs.

December 16, Philadelphia, PA – Kyfora Bio, the innovative bioprocessing company and a leading provider of transfection reagents and services, has announced the launch of its AmpliFect™ GMP Transfection Enhancer. This addition to the AmpliFect™ product line is manufactured under current Good Manufacturing Practice (cGMP) standards to enhance viral vector production for cell and gene therapy (CGT) applications, supporting seamless scalability from process development through commercial manufacturing.
“When developing viral vector-based therapies, effective and low-cost solutions are essential to making them commercially viable,” said Andrew Ott, CEO of Kyfora Bio. “At Kyfora Bio, we leverage our long history in specialty chemicals and our expertise in transfection reagents and excipients to support CGT manufacturers in overcoming these challenges.”
Engineered to integrate effortlessly with Kyfora Bio’s MAXgene® GMP transfection reagent workflows, the AmpliFect™ GMP Transfection Enhancer optimizes plasmid DNA delivery to both suspension and adherent HEK 293 cells. This enhancement increases the titers of recombinant AAV and LV vectors by over twofold, providing a reliable and efficient GMP solution to meet the demands of commercial viral vector production. AmpliFect™ GMP Transfection Enhancer combines the proven performance of research-grade products with the stringent validation and compliance standards required for GMP manufacturing.
“With the ability to increase AAV titers significantly with AmpliFect™ Transfection Enhancer together with our MAXgene GMP PEI transfection reagent allows CGT manufacturers to double the doses produced in a single bioreactor run at a significantly low cost compared to market alternates,” added Leena Mol Thuruthippallil,PhD, VP of Commercial Business at Kyfora Bio. “This innovative product is designed to help meet the increasing demand for CGTs.”
About Kyfora Bio, LLC
Kyfora Bio, a Polysciences subsidiary, is a leading provider of transfection reagents and excipients to support the development of cell and gene therapy (CGT) advancements from bench to clinic. Drawing on over 60 years of expertise in specialty chemical development, manufacturing, and application, Kyfora Bio supplies research-grade to cGMP-compliant transfection reagents and excipients for viral vector production, mRNA vaccines, and other drug delivery applications. Our scalable and cost-effective cGMP solutions empower advanced therapies that aim to transform patient lives.
For more information, please visit www.kyforabio.com.